Navigation Links
Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
Date:2/26/2009

cts.

Diazepam, a long established benzodiazepine, is available in IV and rectal forms for the treatment of epileptic seizures including Acute Repetitive Seizures "ARS" (also described as Bouts of Increased Seizure Activity, 'BISA' or 'breakthrough seizures') in patients with refractory epilepsy. These two routes of administration are associated with significant logistical and compliance issues, especially as treatments are usually administered while a patient is having a seizure. Archimedes IN Diazepam is a simple low-volume solution, which can be delivered in simple, off-the-shelf nasal spray devices offering similar efficacy but potentially greater convenience and acceptability compared to IV and rectal diazepam. IN diazepam has been developed as a ready-to-use disposable nasal spray that can be carried by the patient for immediate use when required.

Archimedes estimates that ARS/BISA affects over 1 million patients in Europe and the US.

About Archimedes Pharma

Archimedes Pharma is a fast-growing specialty pharmaceutical company marketing an expanding portfolio of products to specialist prescribers in Europe whilst building a platform for its future growth through the development of a high-value pipeline from its world-class drug delivery technologies.

Archimedes has an established commercial presence in major European markets and is growing through in-licensing and acquisition of late stage and approved products. It is also building a robust pipeline of in-house products in pain, Parkinson's disease and critical care by applying its drug delivery technologies to proven molecules which have yet to achieve their market potential due to their current mode of delivery. This approach greatly reduces the development risk while promising significant clinical - and thus commercial - benefits. Archimedes' lead product NasalFent(R), uses the Company's PecSys(TM) technology to prod
'/>"/>

SOURCE Archimedes Pharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimers Biomarker Assay
2. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
3. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
4. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
7. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
8. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
9. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
10. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
11. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...USTON, Nov. 6 Cyberonics...ompany will report financial results for the secon...r ending April 30, 2010 on Wednesday, November 18,...conference call to discuss those results on Thursd...al Year 2010 Second Quarter Results Conference Cal...
(Date:11/6/2009)...N DIEGO, Nov. 6 California America...9 as "No Drugs Down the Drain" week for its San Di...aign sponsored by public and private agencies alik...ical pollution in our source water supplies. ,,...omers are encouraged to drop off expired or unwant...
(Date:11/5/2009)...INT RICHMOND, Calif., Nov. 5 /PRNewswire-FirstCall...T ), a specialty pharmaceutical company focused on...ary products that address important therapeutic ne...it will host a webcast and teleconference with man...sults on Thursday, November 12, 2009, at 5:00 p.m....
Breaking Medicine Technology:Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2Statement From the National Pork Board on Testing of Pigs for H1N1 59692 1Omnicell to Release Third Quarter 2009 Earnings Results on October 22 59690 1Omnicell to Release Third Quarter 2009 Earnings Results on October 22 59690 2Virginia Restaurants Urged to Go Completely Smoke Free After Major Report Finds Smoke Free Laws Prevent Heart Attacks 59687 1Virginia Restaurants Urged to Go Completely Smoke Free After Major Report Finds Smoke Free Laws Prevent Heart Attacks 59687 2Virginia Restaurants Urged to Go Completely Smoke Free After Major Report Finds Smoke Free Laws Prevent Heart Attacks 59687 3
...U, Jan. 7 Hawaii Biotech, Inc. announced today,th...and Drug Administration,(FDA) that it may proceed ...uman volunteers with its recombinant, subunit West...ngle site in Hawaii, which the company currently,e...completion of financing,sufficient funding to comp...
...IK, Iceland, Jan. 6 deCODE scientists today,repor... the company has,linked to increased risk of heart... in risk of abdominal aortic aneurysm (AAA) and in... genetic variant ever found to,associate with eith...ce,variant on 9p21 associates with myocardial infa...
Other Medicine Technology:Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials 2Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease 2Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease 3
(Date:11/8/2009)...f H.R. 3961 to Secure the Stability of Medicare ,...atement Attributable to: J. James Rohack, M.D., Pr...: http://www.newscom.com/cgi-bin/prnh/20081209/A... House health reform bill, which will help improve... calls for swift passage of H.R. 3961 to secure th...
(Date:11/8/2009)...e of Health Care Reform Bill ,, Critical legi...e for all Americans ,, BALTIMORE, Nov. 7 /PRNe...d States House of Representatives passed critical ...en Medicare for seniors and end discrimination by ...ans out of affordable health coverage. ,, The A...
(Date:11/7/2009)...re-USNewswire/ -- The American Medical Association...for Citizenship and Community Service to Manus C. ...The award recognizes physicians who have gone abov...ke an outstanding public service contribution to t... today during the opening session of the 2009 Inte...
(Date:11/7/2009)...e-USNewswire/ -- Members of the AMA are trying a l...tion rescinding the AMA,s support of HR 3962. ,...ponsible to their PATIENTS, not the leadership of ...for the Association of American Physicians and Sur...r medical groups. ,, "If the AMA leadership ig...
(Date:11/7/2009)...wire-USNewswire/ -- Speaker Nancy Pelosi and Democ...noon following a Democratic Whip meeting with Pres...the Speaker,s opening remarks: ,, "Thank you v...for us to receive the President of the United Stat... our vote and making progress for the American peo...
Breaking Medicine News(10 mins):Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:AARP Maryland Key Vote News Alert 2Health News:AARP Maryland Key Vote News Alert 3Health News:AMA Honors IL Ophthalmologist Manus C. Kraff M.D. for Volunteer Eye Care for Military Members 2Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2
...Biotechnologies ( www.epeiusbiotech.com ) today ... Rexin-G, a tumor-targeted anti-cancer agent desig...t have spread throughout the body. While Rexin-G i... I/II studies and a Phase II confirmatory trial in...
...nd Patient Advocacy Efforts , , SAN DIEGO, May 18... announced awards received at the American Thoraci...Diego, Calif. being held this week. The ATS meeti...that, to date, has funded $400,000 in new pulmonar...
...dent of the Pharmaceutical analytics company Eular...l if you are making the wrong marketing decision. ...on the latest techniques, strategies and analysis,...1 Northumberland Avenue, Trafalgar Square. London,...
...nown effect of healthcare reform create unpreceden...an, Inc., one of the premier global consulting and...al medical spending for its "typical American fami...ighest since 2006. , , The Milliman Medical Index...
...e Therapeutics, Inc. announced today that it has...h the addition of Pratik Multani, M.D., M.S., as V...than a decade of clinical development experience, ...or therapeutic purposes. SCMs can potentially be ...
... promise for better protection against flu , ...ade up of virus-like particles (VLPs) could provid...lu viruses than conventional vaccines, researchers...nes, according to research presented May 18 at the...
Other Medicine News:Health News:Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009 2Health News:Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference 2Health News:Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference 3Health News:MEDIA ALERT - Eularis to Hold Pharmaceutical Marketing ROI MasterClass in London 2Health News:Milliman Indicates 2009 Medical Cost for 'American family of four' Exceeds $16,700 Based on 7.4% Cost Increase 2Health News:Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators 2Health News:Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators 3Health News:Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators 4Health News:New Methods Could Speed Production of Flu Vaccines 2
The Ultima 2000 SE Argon Laser System
Meridian Microruptor V Nd YAG Laser
Desmarres Chalazion Clamps
Farnsworth Panel D15 test evaluation
Medicine Products: